V-Bio Ventures et al. invest €37m in Camel-IDS

The round, led by Belgian investors V-Bio Ventures and Gimv, saw Swedish HealthCap, Danish Novo Seeds, Israeli Pontifax and Swiss BioMedPartners also invest in the biotech business, alongside previous investors.

Camel-IDS previously received seed funding from the Belgian Foundation Fournier-Majoie and three seed investors, complemented with non-dilutive funding from Brussels-based institute Innoviris.

The proceeds will enable the business to run a trial with its lead program CAM-H2, which targets HER2-positive brain metastatic breast cancer, while further progressing and broadening its pre-clinical pipeline.

Company
Founded in 2014 in a spin-out from Vrije Universiteit Brussel (VUB), Camel-IDS develops radiopharmaceuticals helping breast cancer patients. The business is based in Brussels. 

People
Camel-IDS – Ruth Devenyns (CEO).
Gimv – Karl Naegler (partner).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Early-stage
• Benelux
• Healthcare
• Belgium
• Gimv
• Venture